ARK Invest bought 1.25M shares of Recursion Pharmaceuticals for $4.33M ARK added 37,075 CRISPR Therapeutics shares worth $1.97M PagerDuty was the biggest sell at $3.89M for 566,650 shares ARK also cut ...
Abstract: This paper studies the control-oriented recursive identification of finite impulse response systems with binary-valued observations. Inspired by the Maximum Likelihood method, a novel ...
Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...
Hosted on MSN
If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today
Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...
aRobert N. Butler Columbia Aging Center, Columbia University, New York, NY, USA bDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA cCarolina ...
Today, a brief rundown of news involving Insmed and Recursion Pharmaceuticals, as well as updates from Odyssey Therapeutics, Gilead Sciences and Novo Nordisk that you may have missed.
Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Agent workflows make transport a first-order ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results